Prompt versus preemptive intervention for EBV lymphoproliferative disease - PubMed (original) (raw)
. 2004 May 15;103(10):3979-81.
doi: 10.1182/blood-2003-12-4287. Epub 2004 Jan 29.
Affiliations
- PMID: 14751931
- DOI: 10.1182/blood-2003-12-4287
Free article
Prompt versus preemptive intervention for EBV lymphoproliferative disease
Hans-Joachim Wagner et al. Blood. 2004.
Free article
Abstract
Posttransplantation lymphoproliferative disorders (PTLDs) caused by uncontrolled expansion of Epstein-Barr virus (EBV)-infected B cells after hematopoietic stem cell transplantation (HSCT) can be predicted by an increase in EBV DNA in peripheral blood mononuclear cells. We used real-time quantitative polymerase chain reaction (RQ-PCR) analysis to determine whether frequent monitoring of EBV DNA to allow preemptive treatment is truly of value in patients after HSCT. More than 1300 samples from 85 recipients were analyzed. No patient with consistently low EBV DNA levels developed PTLD. Nine patients had a single episode with a high EBV load (more than 4000 EBV copies/microg peripheral blood mononuclear cell [PBMC] DNA), and 16 patients had high EBV loads detected on 2 or more occasions. Only 8 of these developed symptoms consistent with PTLD, and all were promptly and successfully treated with EBV-specific cytotoxic T cells or CD20 monoclonal antibody. Hence, quantitative measurement of EBV DNA may best be used to enable the prompt rather than the preemptive treatment of PTLD.
Similar articles
- Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A, Prete A, Belotti T, Gibertoni D, Piccirilli G, Gabrielli L, Pession A, Lazzarotto T. Chiereghin A, et al. Transpl Infect Dis. 2016 Feb;18(1):44-54. doi: 10.1111/tid.12485. Epub 2016 Jan 30. Transpl Infect Dis. 2016. PMID: 26574232 - Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
Merlino C, Cavallo R, Bergallo M, Giacchino F, Bollero C, Negro Ponzi A, Cavallo G. Merlino C, et al. New Microbiol. 2003 Apr;26(2):141-9. New Microbiol. 2003. PMID: 12737195 - Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients.
Stevens SJ, Verschuuren EA, Pronk I, van Der Bij W, Harmsen MC, The TH, Meijer CJ, van Den Brule AJ, Middeldorp JM. Stevens SJ, et al. Blood. 2001 Mar 1;97(5):1165-71. doi: 10.1182/blood.v97.5.1165. Blood. 2001. PMID: 11222357 - Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
Styczynski J, Einsele H, Gil L, Ljungman P. Styczynski J, et al. Transpl Infect Dis. 2009 Oct;11(5):383-92. doi: 10.1111/j.1399-3062.2009.00411.x. Epub 2009 Jun 23. Transpl Infect Dis. 2009. PMID: 19558376 Review. - Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.
Gulley ML, Tang W. Gulley ML, et al. Clin Microbiol Rev. 2010 Apr;23(2):350-66. doi: 10.1128/CMR.00006-09. Clin Microbiol Rev. 2010. PMID: 20375356 Free PMC article. Review.
Cited by
- Epstein-barr virus related lymphoproliferations after stem cell transplantation.
Sica S, Metafuni E, Bellesi S, Chiusolo P. Sica S, et al. Mediterr J Hematol Infect Dis. 2009 Dec 14;1(2):e2009019. doi: 10.4084/MJHID.2009.019. Mediterr J Hematol Infect Dis. 2009. PMID: 21416005 Free PMC article. - Clinical characteristics and outcomes of Epstein-Barr virus viral load after allogeneic hematopoietic stem cell transplantation.
Tsushima T, Masuda SI, Yoda N, Kainuma S, Kimeda C, Konno S, Tanaka K, Matsuo K, Shimoji S, Kimura K, Arai H, Utsu Y, Imadome KI, Aotsuka N. Tsushima T, et al. Ann Hematol. 2024 Mar;103(3):935-946. doi: 10.1007/s00277-023-05596-6. Epub 2023 Dec 29. Ann Hematol. 2024. PMID: 38157001 Free PMC article. - Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation.
Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA, Wagner JE. Brunstein CG, et al. Blood. 2006 Oct 15;108(8):2874-80. doi: 10.1182/blood-2006-03-011791. Epub 2006 Jun 27. Blood. 2006. PMID: 16804113 Free PMC article. - Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE. Bollard CM, et al. J Exp Med. 2004 Dec 20;200(12):1623-33. doi: 10.1084/jem.20040890. J Exp Med. 2004. PMID: 15611290 Free PMC article. - Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.
Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, Wu MF, Weiss HL, Gee AP, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Louis CU, et al. Blood. 2009 Mar 12;113(11):2442-50. doi: 10.1182/blood-2008-05-157222. Epub 2008 Oct 29. Blood. 2009. PMID: 18971421 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources